Vaccines and Related Biological Products Advisory Committee – 9/17/2021

November 2, 2021 3:31 pm
Join us for a Vaccines and Related Biological Products Advisory Committee meeting to discuss Pfizer-BioNTech’s supplemental Biologics License Application for administration of a third dose, or “booster” dose, of the COVID-19 vaccine, Comirnaty, in individuals 16 years of age and older. Watch live captions here: https://www.captionedtext.com/client/…
Category: News
About The Author
-
Previous

CDC & FDA Okay Booster Shots For Some Americans | The View
Next

FDA Advisory Panel Unanimously Recommends Moderna Booster Shots Against Covid

Related Videos

Stakeholder Call: COVID-19 Vaccine Booster Doses – 10/22/21

Stakeholder Call: COVID-19 Vaccine Booster Doses – 10/22/21

FDACDC Phase2

Myths and Facts about COVID-19 Vaccines

FDA: Vaccine benefits outweigh risks for young kids

FDA: Vaccine benefits outweigh risks for young kids

FDACDC Phase4

Pfizer/BioNTech COVID-19 vaccine effectiveness drops after 6 months, study shows

FDA committee meets to debate and vote on Covid booster shots for the general public — 9/17/21

FDA committee meets to debate and vote on Covid booster shots for the general public — 9/17/21

LIVE: FDA advisory panel to vote on J&J Covid booster shots — 10/15/2021

LIVE: FDA advisory panel to vote on J&J Covid booster shots — 10/15/2021